Avadel Pharmaceuticals PLC

NASDAQ:AVDLUnited States

Today

Show headlines and story abstract

• European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Wednesday Trading, from 17 minutes ago by MT Newswires

  17 minutes ago by MT Newswires
  Companies Mentioned: AVDL, FMS, BUD, TEF, SQNS, GRFS, TRVG, NCNA, AMRN, AUTL, GNFT, AKTX, CALT, CRH, ADAP, BDRX
  11:26 AM EDT, 05/08/2024 (MT Newswires) -- European equities traded in the US as American depositary receipts were trending modestly higher late Wednesday morning, rising 0.34% to 1,399.71 on the S&P Europe Select ADR Index. From continental Europe,...

• DJ Avadel Pharmaceuticals Price Target Maintained With a $22.00/Share by Needham, from 2 hours ago by Dow Jones

  2 hours ago by Dow Jones
  Companies Mentioned: AVDL
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/AVDL/analyst-ratings
  
  (END) Dow Jones Newswires
  
  May 08, 2024 09:37 ET (13:37 GMT)
  

• Avadel Pharmaceuticals Q1 Loss Narrows, from 2 hours ago by MT Newswires

  2 hours ago by MT Newswires
  Companies Mentioned: AVDL
  09:36 AM EDT, 05/08/2024 (MT Newswires) -- Avadel Pharmaceuticals (AVDL) reported a Q1 net loss Wednesday of $0.30 per diluted share, narrowing from a loss of $0.48 a year earlier. Analysts polled by Capital IQ expected a loss of $0.23. Net product ...

• Avadel Pharmaceuticals Provides Corporate Update and Reports First Quarter 2024 Financial Results, from 4 hours ago by GlobeNewswire

  4 hours ago by GlobeNewswire
  Companies Mentioned: AVDL

• Avadel Pharmaceuticals Provides Corporate Update and Reports First Quarter 2024 Financial Results, from 4 hours ago by Dow Jones

  4 hours ago by Dow Jones
  Companies Mentioned: AVDL
  31, 2023 960 898 Additional paid-in capital 874,018 855,452 Accumulated deficit (772,838) (745,496) Accumulated other comprehensive loss (23,756) (23,167) ----------- -------------- Total shareholders' equity 78,384 87,739 ----------- -------------- Total liabilities and shareholders' equity $ 167,899 $ 164,698 =========== ============== AVADEL PHARMACEUTICALS PLC CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (In thousands) (Unaudited) Three Months Ended March 31, -------------------------------------- 2024 2023 ---------- Cash flows from operating activities: Net loss $ (27,342) $ (30,784) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization 541 588 Amortization of debt discount and debt issuance costs -- 1,873 Share-based compensation expense 5,389 1,522 Other adjustments (719) (1) Net changes in assets and liabilities Accounts receivable (10,589) -- Inventories (1,260) -- Prepaid expenses and other current assets (6,093) (4,131) Research and development tax credit receivable (17) -- Accounts payable & other current liabilities 7,528 468 Accrued expenses 3,415 348 Other assets and liabilities (557) (116) ----------- ---------- Net cash used in operating activities (29,704) (30,233) ----------- ---------- Cash flows from investing activities: Proceeds from sales of marketable securities 119,066 15,295 Purchases of marketable securities (97,679) (10,229) ----------- ---------- Net cash provided by investing activities 21,387 5,066 ----------- ---------- Cash flows from financing activities: Proceeds received in advance of Series B Preferred Shares Issuance -- 40,000 Payments for February 2023 Notes -- (17,500) Proceeds from issuance of shares off the at-the-market offering program 9,250 11,913 Proceeds from stock option exercises and employee share purchase plan 3,940 29 ----------- ---------- Net cash provided by financing activities 13,190 34,442 ----------- ---------- Effect of foreign currency exchange rate changes on cash and cash equivalents (246) 135 Net change in cash and cash equivalents 4,627 9,410 Cash and cash equivalents at January 1, 31,167 73,981 ----------- ---------- Cash and cash equivalents at March 31, $ 35,794 $ 83,391 =========== ==========